Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Biotechnical Methods Section BTS
  • Published:

Biotechnical Methods Section (BTS)

Quantitation of DNA topoisomerase IIα and β in human leukaemia cells by immunoblotting

Leukemia volume 14, pages 1997–2005 (2000)Cite this article

Abstract

DNA topoisomerase II (topo II) is an essential nuclear enzyme and is the target for etoposide, which is used in the therapy of childhood acute lymphoblastic leukaemia (ALL). Topo II exists as two isoforms referred to as topo IIα and topo IIβ. To determine whether cellular levels of topo IIα and β are an important factor in determining drug sensitivity/resistance requires accurate, precise measurements of the two isoforms. We have developed a quantitative Western blotting method to accurately measure the absolute amounts of human topo IIα and β, using recombinant human topo IIα and β as standards. This quantitative method has been used to assess the efficiency of several commonly used topo II extraction protocols. The extractable amount of topo IIα and β was found to be salt-dependent. However extraction using the optimal salt concentration was found to be as efficient as extraction with DNase I/Rnase A digestion and SDS solubilisation. Using the optimum extraction procedure and the quantitative immunoblotting method, topo IIα and β was quantified in cell lines, peripheral blood lymphocytes and in lymphoblasts from children with newly diagnosed ALL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Wang JC . DNA topoisomerases Ann Rev Biochem 1996 65: 635–692

    Article  CAS  PubMed  Google Scholar 

  2. DiNardo S, Voelkel K, Sternglanz R . DNA topoisomerase II mutant of Saccharomyces cerevisiae topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication Proc Natl Acad Sci USA 1984 81: 2616–2620

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Snapka RM, Powelson MA, Strayer JM . Swiveling and decatenation of replicating simian virus 40 genomes in vivo Mol Cell Biol 1988 8: 515–523

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Adachi Y, Luke M, Laemmli UK . Chromosome assembly in vitro: topoisomerase II is required for condensation Cell 1991 64: 137–148

    Article  CAS  PubMed  Google Scholar 

  5. Drake FH, Hoffmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK . Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II Biochemistry 1989 28: 8154–8160

    Article  CAS  PubMed  Google Scholar 

  6. Willmore E, Frank AJ, Padget K, Tilby MJ, Austin CA . Etoposide targets topoisomerase IIα and IIβ in leukaemia cells: isoform-specific cleavable complexes visualised and quantified in situ by a novel immunofluorescence technique Mol Pharmacol 1998 53: 78–85

    Article  Google Scholar 

  7. Beck WT, Kim R, Chen M . Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumour cells Cancer Chemother Pharmacol 1994 34: S14–S18

    Article  CAS  PubMed  Google Scholar 

  8. Chen AY, Liu LF . DNA topoisomerases: essential enzymes and lethal targets Ann Rev Pharmacol Toxicol 1994 34: 191–218

    Article  CAS  Google Scholar 

  9. Webb CD, Latham MD, Lock RB, Sullivan DM . Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line Cancer Res 1991 51: 6543–6549

    CAS  PubMed  Google Scholar 

  10. Eijdems EWHM, Borst P, Jongsma APM, DeJong S, De Viries EGE, Van Groenigen M, Versantvoort CHM, Nienwint AWM, Baas F . Genetic transfer of non-P-glycoprotein-mediated multi-drug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype Proc Natl Acad Sci USA 1992 89: 3498–3502

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Brown GA, McPherson JP, Hedley DW, Toso R, Deuchars L, Freedman MH, Goldenburg GJ . Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukaemia cell lines Cancer Res 1995 55: 78–82

    CAS  PubMed  Google Scholar 

  12. Dereuddre S, Delaporte C, Jacquemin Sablon A . Role of topoisomerase IIβ in the resistance of 9-OH-elliptincine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors Cancer Res 1997 57: 4301–4308

    CAS  PubMed  Google Scholar 

  13. Wasserman RA, Austin CA, Fisher LM, Wang JC . Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast Cancer Res 1993 53: 3591–3596

    CAS  PubMed  Google Scholar 

  14. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC, Fisher ML . Expression, domain structure and enzymatic properties of an active recombinant human DNA topoisomerase IIβ J Biol Chem 1995 270: 15739–15746

    Article  CAS  PubMed  Google Scholar 

  15. Raychandauri P, Rooney R, Nevins JR . Identification of an E1A-inducible cellular factor that interacts with regulatory sequences within the adenovirus E4 promoter EMBO J 1987 6: 4073–4081

    Article  Google Scholar 

  16. Mirski SEL, Evans CD, Almquist KC, Slovak ML, Cole SPC . Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16 Cancer Res 1993 53: 4866–4873

    CAS  PubMed  Google Scholar 

  17. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT . Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukaemic cells selected for resistance to VM-26 Biochemistry 1988 27: 8861–8869

    Article  CAS  PubMed  Google Scholar 

  18. Cowell IG, Willmore E, Charlton D, Marsh KL, Jazrawi E, Fisher LM, Austin CA . Nuclear distribution of human DNA topoisomerase IIβ: a nuclear targeting signal resides in the 116-residue C-terminal tail Exp Cell Res 1998 243: 232–240

    Article  CAS  PubMed  Google Scholar 

  19. Issacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID . Physiological regulation of eukaryotic topoisomerase II Biochim Biophys Acta 1998 1400: 121–137

    Article  Google Scholar 

  20. Darby MK, Schmitt B, Jongstra Bilen J, Vosberg HP . Inhibition of calf thymus type II DNA topoisomerase by poly (ADP)-ribosylation EMBO J 1985 4: 2129–2134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Medical Research Council UKALL XI (92) Trial for Childhood Acute Lymphoblastic Leukaemia

  22. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH . Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells Cell Growth Diff 1991 2: 209–214

    CAS  PubMed  Google Scholar 

  23. Kaufmann SH, McLaughlin SJ, Kastan MB, Liu LF, Karp JE, Burke PJ . Topoisomerase II levels during granulocytic maturation in vitro and in vivo Cancer Res 1991 51: 3534–3543

    CAS  PubMed  Google Scholar 

  24. Prosperi E, Sala E, Negri C, Olianti C, Supino R, Astraldi Ricotti GBC, Bottirola G . Topoisomerase IIα and β in human tumour cells grown in vitro and in vivo Anticancer Res 1992 12: 2093–2100

    CAS  PubMed  Google Scholar 

  25. Woessner RD, Chung TD, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH, Johnson RK . Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II Cancer Res 1990 50: 2901–2908

    CAS  PubMed  Google Scholar 

  26. Meczes EL, Marsh KL, Fisher LM, Rogers MP, Austin CA . Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2beta construct allows the study of topoisomerase IIβ inhibitors in yeast Cancer Chemother Pharmacol 1997 39: 367–375

    Article  CAS  PubMed  Google Scholar 

  27. Errington F, Willmore E, Tilby MJ, Li L, Li G, Baguley BC, Austin CA . Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation Mol Pharmacol 1999 56: 1309–1316

    Article  CAS  PubMed  Google Scholar 

  28. Taagepera S, Rao PN, Drake FH, Gorbsky GJ . DNA topoisomerase IIα is the major chromosome protein recognised by the mitotic phosphoprotein antibody MPM-2 Proc Natl Acad Sci USA 1993 90: 8407–8411

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Prosperi E, Negri C, Marchese G, Astaldi Ricotti GCB . Expression of the 170-kDa and 180-kDa isoforms of DNA topoisomerase II in resting and proliferating lymphocytes Cell Prolif 1994 27: 257–267

    Article  CAS  PubMed  Google Scholar 

  30. Kimura K, Saijo M, Ui M, Enomoto T . Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase J Biol Chem 1994 269: 1173–1176

    CAS  PubMed  Google Scholar 

  31. Turley KM, Comley M, Houlbrook S, Nozaki N, Kikuchi A, Hickson ID, Gatter K, Harris AL . The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues Br J Cancer 1997 75: 1340–1346

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Heck MM, Earnshaw WC . Topoisomerase II: a specific marker for cell proliferation J Cell Biol 1986 103: 2569–2581

    Article  CAS  PubMed  Google Scholar 

  33. Hirt A, Werren EM, Luethy AR, Gerdes J, Wagner HP . Cell cycle analysis in lymphoid neoplasia of childhood: differences among immunologic subtypes and similarities in the proliferation of normal and leukaemic precursor B cells Br J Haematol 1992 80: 189–193

    Article  CAS  PubMed  Google Scholar 

  34. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ . Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukaemia Blood 1994 83: 517–530

    CAS  PubMed  Google Scholar 

  35. Kaufmann SH, Karp JE, Burke PJ, Gore SD . Addition of etoposide to initial therapy of adult acute lymphoblastic leukaemia: a combined clinical and laboratory study Leuk Lymphoma 1996 23: 71–83

    Article  CAS  PubMed  Google Scholar 

  36. Zhou R, Vitols S, Gruber A, Liliemark J, Wang Y, Liliemark E . Etoposide-induced DNA strand breaks in relation to P-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL Br J Haematol 1999 105: 420–427

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Kay Kendall Leukaemia Research Fund. We thank Dr M Reid and Dr A Hall for providing patient samples and also Prof DR Newell for helpful discussions.

Author information

Authors and Affiliations

  1. School of Biochemistry and Genetics, The Medical School, University of Newcastle upon Tyne, UK

    K Padget & CA Austin

  2. Department of Child Health, Royal Victoria Infirmary, Newcastle upon Tyne, UK

    ADJ Pearson

Authors
  1. K Padget
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. ADJ Pearson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. CA Austin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Padget, K., Pearson, A. & Austin, C. Quantitation of DNA topoisomerase IIα and β in human leukaemia cells by immunoblotting. Leukemia 14, 1997–2005 (2000). https://doi.org/10.1038/sj.leu.2401928

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401928

Keywords

This article is cited by

Search

Advanced search

Quick links